Cusatuzumab

Published

dm+d

Unassigned

New Medicines

High risk myelodysplastic syndromes (MDS)

Information

New molecular entity
Janssen
Janssen

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

IgG1 monoclonal antibody targeting CD70, an immune checkpoint target involved in haematological malignancies, several solid tumours and severe autoimmune diseases
The incidence of MDS is approximately 4 per 100,000 population/year. It is predominantly a disease of the elderly with an incidence of over 30 per 100,000 per year in those over the age of 70 years [1].
High risk myelodysplastic syndromes (MDS)
Intravenous infusion